Comparison of therapeutic antibiotic treatments on tissue-engineered human skin substitutes.
For regenerative medicine to gain clinical acceptance, the effects of commonly used treatment regimens on bioengineered organs must be considered. The antibiotics mafenide acetate (mafenide) and neomycin plus polymyxin (neo/poly) are routinely used to irrigate postoperative skin grafts on contaminated wounds. The effects of these clinically used antibiotics were investigated using tissue-engineered human skin substitutes generated with primary human keratinocytes or the near-diploid human keratinocyte cell line, Near-diploid Immortal Keratinocytes. Following topical or dermal treatment, the skin substitutes were assayed for viability, tissue morphology, glycogen content, and the expression of active caspase 3. Mafenide, but not neo/poly, induced morphological and biochemical changes in tissue-engineered skin substitutes. Keratinocytes in all histological layers of mafenide-treated skin substitutes exhibited ballooning degeneration and glycogen depletion. Mafenide-treatment also triggered separation of basal keratinocytes from the underlying dermis. None of the antibiotic treatments induced apoptosis, as measured by active caspase 3 immunostaining. The results demonstrate that mafenide, but not neo/poly, is detrimental to the viability and structural integrity of tissue-engineered human skin substitutes. These findings highlight the need to identify treatment regimens that are compatible with and hence enable the therapeutic efficacy of first-generation bioengineered organs such as skin.
Gibson
Angela L
AL
Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Schurr
Michael J
MJ
Schlosser
Sandy J
SJ
Comer
Allen R
AR
Allen-Hoffmann
B Lynn
BL
D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D001672:Biocompatible Materials; D053148:Caspase 3 / Q000378:metabolism; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D006003:Glycogen / Q000378:metabolism; D006801:Humans; D015603:Keratinocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D008272:Mafenide / Q000009:adverse effects / Q000627:therapeutic use; D008422:Materials Testing; D009355:Neomycin / Q000627:therapeutic use; D011113:Polymyxins / Q000627:therapeutic use; D017768:Skin, Artificial; D023822:Tissue Engineering / Q000379:methods*
D000900:Anti-Bacterial Agents; D001672:Biocompatible Materials; D011113:Polymyxins; D008272:Mafenide; D006003:Glycogen; C505407:CASP3 protein, human; D053148:Caspase 3; D009355:Neomycin